Carl Starfelt ruled out for remainder of season after L5-S1 herniated disc diagnosis
Carl Starfelt sidelined with an L5-S1 herniated disc; Celta confirm conservative treatment and a 2-3 week reassessment with surgery not ruled out for the season.
Carl Starfelt has been diagnosed with a herniated disc at the L5-S1 level and is continuing conservative treatment while awaiting reassessment, Celta Vigo confirmed on Friday. The centre-back met this week with Madrid-based neurosurgeon Dr. Pedro Mata, who reviewed imaging and clinical findings that identified the lumbar disc injury. The club stressed that Starfelt’s return is dependent on his response to recent epidural therapy and further evaluation, making a comeback this season unlikely. This diagnosis also casts significant doubt on his availability for Sweden’s upcoming World Cup squad.
Starfelt diagnosed with L5-S1 herniated disc
The club’s medical statement said that Starfelt developed worsening low back symptoms that became more pronounced during international duty at the end of March. A lumbar MRI confirmed a herniated disc at the L5-S1 level, a problem commonly associated with radicular pain and limitations for high-intensity physical activity. Medical staff sought a specialist opinion from Dr. Pedro Mata in Madrid to corroborate the imaging and advise on a management plan. That consultation underlined the need to pursue non-surgical therapies initially while monitoring neurological status closely.
Club medical update and conservative treatment plan
Celta’s medical department detailed the conservative measures already employed, which include medication, a structured physiotherapy program, spinal distraction techniques and several epidural injections. The club noted that the most recent epidural injection was administered this week as part of an effort to reduce inflammation and nerve irritation. According to the statement, Starfelt has shown notable clinical improvement but remains limited in his ability to perform football-specific activities. The multidisciplinary team will continue to manage pain control and mobility while assessing whether symptoms and function can return to a level compatible with professional play.
Surgical option to be reconsidered after a 2–3 week review
While the initial approach is non-operative, Celta confirmed that surgery has not been ruled out and could be considered if Starfelt’s recovery stalls. The club indicated that a formal reassessment of his response to the latest injection and ongoing therapies will take place in approximately two to three weeks. That reassessment will inform whether continued conservative care is reasonable or whether referral for surgical intervention is appropriate. Club doctors emphasized that any decision would weigh the athlete’s long-term spinal health alongside the practical timing of competitive fixtures.
Absence from Celta and immediate squad impact
Starfelt has not featured for Celta since March 15 and has missed the team’s last seven official matches due to the lumbar problem. His absence removes a regular option at centre-back for the club during a key run of fixtures, forcing tactical adjustments and increased minutes for other defenders. Celta’s coaching staff have had to reshuffle the back line and alter preparation plans while the medical team works to expedite a safe return. The club did not provide a firm timeline for reintegration into full training, citing the need for objective improvement before match involvement.
Consequences for Sweden and the World Cup squad
The diagnosis deals a significant blow to Starfelt’s hopes of featuring for Sweden at the forthcoming World Cup, a tournament he had targeted after helping in qualifying fixtures. The club specifically flagged that the injury makes his participation in the national team’s plans doubtful, given the uncertain recovery trajectory. Starfelt’s most recent competitive minutes came with Sweden as he pursued qualification, but the exacerbation of symptoms following international play has complicated his availability. National team selectors will now have to monitor developments closely and consider alternatives while awaiting Celta’s medical updates.
Medical context and expectations for recovery
A herniated disc at L5-S1 can present a wide range of outcomes, from conservative recovery to the need for surgical decompression, depending on symptom severity and neurological signs. Celta’s medical team reported measurable improvement since initiating treatment, which supports a continued non-surgical pathway for now. The short reassessment window set by the club is intended to establish whether that trend continues and whether the player can safely return to progressive on-field work. Any decision will prioritize the defender’s long-term spinal integrity and functional capacity over a rushed return to competition.
The immediate next steps for Starfelt are clear: continue the prescribed conservative regimen, complete the scheduled follow-up with the multidisciplinary team, and undergo the planned clinical and imaging reassessment in two to three weeks. Celta will update stakeholders after that review and will weigh surgical referral if symptoms plateau or worsen. In the meantime, the club and player will focus on rehabilitation milestones and cautious progression toward training benchmarks that indicate readiness to resume competitive action.
